Table 3.
Associations between c-MET SNPs and clinical outcome among loco-regional gastric cancer patients (stage IB to stage IV; AJCC 6th) in the Japanese cohort
| Disease-free Survival |
Overall Survival |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| SNP | N | Median, yrs (95%CI) |
3-year of recurrence rate ± SE |
HR (95%CI) | HR (95%CI) ‡ | Median, yrs (95%CI) |
5-year of survival rate ± SE |
HR (95%CI) | HR (95%CI) ‡ |
| rs41736 | |||||||||
| T/T | 42 | 2.9 (1.5, 16.1+) | 0.51 ± 0.08 | 1 (Reference) | 1 (Reference) | 4.3 (2.2, 16.1+) | 0.45 ± 0.09 | 1 (Reference) | 1 (Reference) |
| T/C | 82 | 20.1+ (2.9, 20.1+) | 0.40 ± 0.06 | 0.71 (0.42, 1.22) | 0.58 (0.32, 1.05) | 20.1+ (3.4, 20.1+) | 0.60 ± 0.06 | 0.70 (0.39, 1.23) | 0.60 (0.33, 1.11) |
| C/C | 30 | 2.5 (1.3, 7.1+) | 0.52 ± 0.10 | 1.04 (0.54, 2.01) | 0.76 (0.37, 1.55) | 2.8 (1.7, 7.1+) | 0.44 ± 0.10 | 1.20 (0.61, 2.35) | 0.86 (0.42, 1.78) |
| P value† | 0.32 | 0.20 | 0.18 | 0.25 | |||||
| rs41739 | |||||||||
| G/G | 49 | 16.1+ (2.0, 16.1+) | 0.46 ± 0.07 | 1 (Reference) | 1 (Reference) | 16.1+ (2.8, 16.1+) | 0.54 ± 0.08 | 1 (Reference) | 1 (Reference) |
| G/A | 72 | 20.1+ (2.2, 20.1+) | 0.44 ± 0.06 | 0.92 (0.54, 1.58) | 0.74 (0.43, 1.28) | 20.1+ (3.1, 20.1+) | 0.54 ± 0.07 | 0.97 (0.54, 1.71) | 0.77 (0.43, 1.38) |
| A/A | 33 | 2.9 (1.3, 7.1+) | 0.51 ± 0.09 | 1.25 (0.67, 2.33) | 0.93 (0.47, 1.82) | 4.1 (1.7, 7.1+) | 0.46 ± 0.10 | 1.48 (0.77, 2.82) | 1.01 (0.50, 2.04) |
| P value† | 0.60 | 0.53 | 0.34 | 0.60 | |||||
| rs40239 | |||||||||
| A/A | 96 | 2.3 (1.6, 20.1+) | 0.55 ± 0.05 | 1 (Reference) | 1 (Reference) | 3.4 (2.3, 20.1+) | 0.45 ± 0.06 | 1 (Reference) | 1 (Reference) |
| A/G* | 53 | 15.2+ | 0.28 ± 0.06 | 0.43 (0.25, 0.74) | 0.48 (0.27, 0.83) | 15.2+ (4.3, 15.2+) | 0.65 ± 0.07 | 0.47 (0.27, 0.81) | 0.50 (0.28, 0.88) |
| G/G* | 9 | ||||||||
| P value† | 0.001 | 0.009 | 0.006 | 0.017 | |||||
| rs1621 | |||||||||
| A/A | 109 | 20.1+ (2.3, 20.1+) | 0.45 ± 0.05 | 1 (Reference) | 1 (Reference) | 20.1+ (3.4, 20.1+) | 0.55 ± 0.05 | 1 (Reference) | 1 (Reference) |
| A/G* | 44 | 3.4 (2.0, 9.0+) | 0.47 ± 0.07 | 1.04 (0.63, 1.70) | 0.89 (0.54, 1.48) | 4.1 (2.7, 9.0+) | 0.48 ± 0.08 | 1.11 (0.66, 1.84) | 0.95 (0.56, 1.60) |
| G/G* | 4 | ||||||||
| P value† | 0.88 | 0.65 | 0.70 | 0.85 | |||||
| rs10234854 | |||||||||
| G/G | 80 | 16.1+ (2.9, 16.1+) | 0.40 ± 0.06 | 1 (Reference) | 1 (Reference) | 16.1+ (4.3, 16.1+) | 0.60 ± 0.06 | 1 (Reference) | 1 (Reference) |
| G/A | 54 | 2.2 (1.3, 20.1+) | 0.54 ± 0.07 | 1.49 (0.90, 2.45) | 1.14 (0.67, 1.95) | 3.9 (2.3, 20.1+) | 0.41 ± 0.08 | 1.60 (0.94, 2.70) | 1.15 (0.66, 2.01) |
| A/A | 20 | 6.5+ (1.4, 6.5+) | 0.37 ± 0.11 | 0.82 (0.37, 1.86) | 0.73 (0.31, 1.72) | 6.5+ (1.9, 6.5+) | 0.60 ± 0.12 | 1.01 (0.44, 2.30) | 0.89 (0.37, 2.12) |
| P value† | 0.19 | 0.58 | 0.18 | 0.80 | |||||
| rs184953 | |||||||||
| C/C | 114 | 3.4 (2.2, 20.1+) | 0.49 ± 0.05 | 1 (Reference) | 1 (Reference) | 5.7 (3.0, 20.1+) | 0.52 ± 0.05 | 1 (Reference) | 1 (Reference) |
| C/A* | 36 | 6.1+ (3.0, 6.1+) | 0.32 ± 0.07 | 0.66 (0.37, 1.19) | 0.69 (0.37, 1.27) | 6.1+ (3.9, 6.1+) | 0.54 ± 0.11 | 0.77 (0.42, 1.39) | 0.75 (0.40, 1.39) |
| A/A* | 6 | ||||||||
| P value† | 0.16 | 0.23 | 0.38 | 0.36 | |||||
*
Combined in the analysis in the dominant genetic model.
†
Based on the log-rank test in the univariable analysis and Wald test in the multivariable analysis within Cox regression model.
+
Estimates were not reached.
‡
Adjusted for stage (I, II, III, and IV), gender, age (<65, 65–74, ≥75 as continuous), and type of adjuvant therapy (no vs yes)